Glaxo Begins Trials for Bird Flu Vaccine
Posted on: Friday, 31 March 2006, 12:00 CST
UK drug giant GlaxoSmithKline is to start an international clinical trial program to test two pandemic vaccines against the H5N1 strain of the avian influenza virus in humans.
The first trial, which has recruited 400 healthy adult volunteers in Germany, is testing a pandemic flu vaccine using a classic alum adjuvant to improve individuals' immune response and possibly allow a lower amount of antigen to be used per dose.
The second study, a clinical trial conducted in Belgium in 400 healthy adults, is testing a possible pandemic flu vaccine that contains a novel adjuvant system. GSK hopes this novel adjuvant will require smaller doses than existing therapies, increasing the company's manufacturing capacity for the vaccine. Such a vaccine would offer governments additional options of stockpiling and vaccinating ahead of a pandemic outbreak.
Both trials are testing the vaccine's safety and ability to boost individuals' immune response against H5N1. Tested vaccines are made from inactivated (killed) H5N1 virus. Different dose levels are being studied. Volunteers are to receive two vaccinations approximately three weeks apart. The studies will allow GSK to select an optimal dose and formulation for subsequent safety trials in groups at high risk of complications following influenza infection, such as children and the elderly.
Preliminary results from the clinical trials are expected in the third quarter of 2006. GSK plans to have a pandemic flu vaccine in production before the end of the year.
"While the first vaccine candidate aims at mounting a strong defense against a pandemic outbreak, the second vaccine may offer governments a preferred option to proactively stockpile and begin vaccination before the onset of a pandemic, significantly increasing the speed of a public health response in the event of an outbreak," said Jean Stephenne, president of GSK's vaccine division.
Source: Datamonitor
Related Articles
- HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials
- Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
- Medicago's H5N1 VLP Vaccine Demonstrates Cross-Reactivity Against Multiple Strains of Avian Flu in Key Ferret Animal Model
- New Vaccine Against Deadliest Strain of Avian Flu Tested By University of Pittsburgh Scientists
- Human Tests Conducted on Fast-Track Avian Flu Vaccine
- CytoDyn DNA Vaccine Shows Promise for Low-Dose Protection From Bird Flu, Reliable Supply
- Sanofi-Aventis Says Flu Vaccine Protects Against New H5N1 Strains
- MedImmune and National Institutes of Health Begin Clinical Testing of a Live, Attenuated Intranasal Vaccine Against an H5N1 Avian Influenza Virus
- Thai Gov't to Vaccinate 150,000 Workers Against Influenza
- Italian AIDS Vaccine Passes First Test
 |
 |
User Comments (0)
RSS Feeds